FDA Approves Advair(R) 250/50 For Reduction Of Exacerbations In Patients With COPD (Medical News Today)
The U.S. Food and Drug Administration approved Advair Diskus(R) 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations. With this approval, Advair becomes the only treatment FDA has approved to reduce COPD exacerbations.

Generic penicillins: boosted by FDA's back-to-basics for S.pneumoniae (Pharmaceutical Business Review)
According to the Infectious Disease Society of North America, the FDA has changed the breakpoints used to determine the susceptibility cut-off for penicillins in the treatment of Streptococcus pneumoniae pneumonia. This will reinvigorate this largely genericized antibiotic class, and is indicative of increasing pressure on antibiotics as efforts are made to restrict antibiotic resistance.